Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-64005 in Major Depressive Disorder (Phase 2, Japan)
jRCT2080225024Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OPC-64005 in major depressive disorder (MDD) (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in MADRS total score at Week 6. Started Jan 2020; status: completed.
02
Drugs
OPC-64005
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2080225024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225024.